Patent · US Active

Treatment of ascites

US11364277B2 · kind B2 · utility

0Cited by
1References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 9, 2019
Grant dateJun 21, 2022
Priority date—
Expiry dateApr 9, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P1/16
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.